Imugene Ltd (ASX:IMU) saw a significant surge in their share price following optimistic early-stage trial results from their prospective cancer drug, VAXINIA. The company's shares escalated by 16.7%, placing it among the top 10 performers on the ASX All Ordinaries index. This rise in the share price coincided with a trading volume crossing 56.2 million shares, a figure considerably higher than the monthly average.
The boost was largely attributed to positive updates on Imugene's Phase 1 MAST trial, which evaluates the safety, tolerability, and early response signals of VAXINIA, a novel cancer-killing virus. The trial, expected to run for 24 months from its initiation in May 2022, demonstrated positive treatment effects in six gastrointestinal cancer patients. The patients included two each with colorectal and bile duct cancers, and one each with pancreatic and liver cancers.
The results showed a disease control rate of 75% without adverse safety signals, suggesting VAXINIA's high therapeutic window and potential as a potent anti-cancer drug for hard-to-treat bile duct cancer. Leslie Chong, Imugene's MD & CEO, hailed VAXINIA as a promising anti-cancer solution.
Despite the recent surge, Imugene's shares have fallen by 61% in 2023 and by 73% over the past year. However, investors who bought shares five years ago are still up by 170%. The trial continues to recruit across 10 US and Australian sites.
InvestingPro Insights
Drawing from InvestingPro's real-time data and expert insights, Imugene's financial performance and investment potential can be further analyzed. According to InvestingPro, the company's revenue growth has been accelerating, and it yields high returns on invested capital. These are positive signs for investors, as they indicate strong financial health and efficient use of capital.
InvestingPro's data shows that Imugene's P/E Ratio (Adjusted) as of Q2 2023 is 13.54, suggesting the company is trading at a low P/E ratio relative to its near-term earnings growth. This could indicate that the stock is undervalued. Moreover, the company's Price / Book ratio for the same period is 4.09, which may be perceived as high, but it can also signify high expectations for the company's future performance.
Finally, the company has maintained dividend payments for 32 consecutive years, a testament to its stable financial position and commitment to returning capital to shareholders. This could be particularly appealing to income-focused investors.
For additional insights and tips, consider exploring InvestingPro's platform. It offers a wealth of information, including over 10 additional tips for Imugene and a multitude of other companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.